Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — Q3 FY2017 Earnings Presentation
16 slides from Dr. Lal Pathlabs's earnings presentation, Feb 2, 2017
Slide 1: Dr. Lal PathLabs Limited (LPL) Q3 & 9M FY17 Results Presentation
Dr. Lal PathLabs Limited (LPL) Q3 & 9M FY17 Results Presentation February 02, 2017
Slide 2: Table of Contents
Table of Contents 1 Overview of Dr. Lal PathLabs 2 Key Highlights 3 Q3 & 9M FY2017 Financial Performance 4 Financial Highlights 5 Operating Highlights 6 Management Commentary 7 Outlook 8 Corporate Overview 9 Contact Us DISCLAIMER: This presentation may contain ‘forward-looking’ statements at places.
Slide 3: Overview of Dr Lal PathLabs
Overview of Dr Lal PathLabs 172 clinical labs (including Established consumer National Reference Lab at healthcare brand in Delhi),1,559 Patient Service diagnostic services Centers (PSCs) and 4,967 Pick-up Points (PUPs)* Scalable model integrated Catalogue of 1,110 test through centralized IT panels
Slide 4: Key Highlights
Key Highlights Performance drivers remain intact and continue to support growth; Momentum decelerated on account of demonetization During Q3 FY17 : Revenues witnessed 10% y-o-y growth to Rs 2,075 million Volume growth slowed to 5% as bulk of walk-ins & network clients were dominated by cash
Slide 5: Q3 & 9M FY17 Financial Performance
Q3 & 9M FY17 Financial Performance Particulars (Rs. mn) Q3 FY17 Q3FY16 Growth % 9M FY17 9M FY16 Growth % Revenues 2,074.7 1,885.7 10.0% 6,924.8 5,936.1 16.7% Total Expenditure 1,605.0 1,185.1 35.4% 5,052.9 4,380.2 15.4% ESOP charges reversal - (273.8) - - (34.7) - Normalised EBITDA (excl ESOP) 469.7
Slide 6: Financial Highlights
Financial Highlights Revenues All figures in Rs mn 2,622 6,925 2,157 2,228 5,936 1,977 2,075 1,893 1,886 Q1FY16 Q2FY16 Q3FY16 Q4FY16 Q1FY17 Q2FY17 Q3FY17 9M FY16 9M FY17 Q3 FY17 revenue performance reflects underlying drivers: Consistent focus on expansion Reaching out to a wider patient pool
Slide 7: Financial Highlights
Financial Highlights All figures in Rs mn Normalised EBITDA excl ESOP 1,872 1,521 470 427 Q3FY16 Q3FY17 9M FY16 9M FY17 Normalized EBITDA post ESOP for the quarter stood at Rs 470 million, growth of 10%, aligned with the moderated revenue trend and reduced operating leverage 7
Slide 8: Financial Highlights
Financial Highlights All figures in Rs mn Normalised PBT (excl ESOP and Excp items) 1,858 1,445 465 396 Q3FY16 Q3FY17 9M FY16 9M FY17 Normalised PBT (excl ESOP & Excp Item) was at Rs 465 million in Q3 FY17; Margins were at 22.4% 8
Slide 9: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs No. of PUPs 1,559 172 5,668 164 1,340 4,967 4,225 1,064 146 824 2,879 131 FY13 FY14 FY15 FY16 FY13 FY14 FY15 FY16 FY13 FY14 FY15 FY16 No. of patients (mn) No. of samples (mn) 26.3 12.0 21.7 22.2 19.0 9.9 10.1 16.0 9.0 7.7 FY13 FY14 FY15 F
Slide 10: Management Commentary
Management Commentary Commenting on the results announcement, Dr. Arvind Lal - Chairman and Managing Director said; “We have designed LPL’s model to deliver sustainable results on the back of a robust infrastructure, systems and processes and built the dexterity to sustain short term incidences whic
Slide 11: Outlook
Outlook Robust operating model best-positioned to capitalize on growth trends in diagnostic services -one of the fastest-growing segments of the Indian healthcare industry Will leverage established position of a strong consumer healthcare brand in diagnostic services . Initiatives to improve brand c
Slide 12: Corporate Overview
Corporate Overview • LPL Strategy for future growth • Experienced Management team 12
Slide 13: LPL Strategy for future growth
LPL Strategy for future growth 1) Strengthen Existing 2) Expansion in Offering Operations 3) Expand management of hospital based and clinical 4) Geographic expansion laboratories 13
Slide 14: LPL Strategy for future growth
LPL Strategy for future growth 1 Strengthen Existing Operations Boosting quality & Improving Grow basic Online initiatives Investment in reliability turnaround times radiology practice and data analytics branding standards for testing 2 Expansion in Offering Improve breadth Preventive Chronic & Life
Slide 15: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Whole-time Director and Chief Chairman and Managing Director Whole-time Director Executive Officer Dilip Bidani Bharath Uppiliappan Shankha Banerjee Chief Financial Officer COO (Strategic Business Unit 1) COO –
Slide 16: Contact us
Contact us About Dr Lal PathLabs Limited (LPL) Dr Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and